Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystic fibrosis liver disease in the post-modulator era.

Current opinion in pulmonary medicine - 1 Nov 2023

Narkewicz Michael R

Abstract excerpt

PURPOSE OF REVIEW: Highly effective modulators of cystic fibrosis transmembrane conductance regulator (CFTR) function have had dramatic impact on pulmonary and nutritional outcomes in persons with cystic fibrosis (pwCF). The impact on liver disease in pwCF was not the focus of the registration trials. The purpose of this review is to assess the current literature on the impact of HEMT on liver disease,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Elasticity Imaging Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Liver Diseases

Share to Liver Transplantation

Share to Mutation

Share to Young Adult

Source

Identifiers

PMID: 37678151
DOI: 10.1097/MCP.0000000000001017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystic fibrosis liver disease in the post-modulator era.PMID 37678151Read ↗

Trials and tribulations of highly effective modulator therapies in cystic fibrosis.Semantic proximity Read ↗

Unmet challenges in cystic fibrosis treatment with modulators.Semantic proximity Read ↗

Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy.Semantic proximity Read ↗

Update on Cystic Fibrosis in Pediatric Patients.Semantic proximity Read ↗

SIMPLIFYing cystic fibrosis treatment in a post-modulator era.Semantic proximity Read ↗

Update on Clinical Outcomes of Highly Effective Modulator Therapy.Semantic proximity Read ↗

Emerging clinical perspectives in cystic fibrosis liver disease.Semantic proximity Read ↗

Nutritional and metabolic management for cystic fibrosis in a post-cystic fibrosis transmembrane conductance modulator era.Semantic proximity Read ↗

Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis.Semantic proximity Read ↗

Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.Semantic proximity Read ↗

Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.